SOPHiA GENETICS SA (SOPH) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning. My name is Kelsey, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Sophia Genetics Third Quarter 2025 Earnings Conference Call. Kellen Sanger, Sophia Genetics Head of Strategy, Investor Relations. You may begin. Thank you, and good morning, everyone. Welcome to the Sophia Genetics Third Quarter 2025 Earnings Conference Call. Joining me today to discuss the results are Dr. Yurgy Kamblong, our co-founder and chief executive officer, Ross Mukin, our company president, and George Cardosa, our chief financial officer. I'd like to remind you that management will make statements during this call that are forward-looking statements within the meetings of federal securities law. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements. Additional information regarding these risks, uncertainties, and factors that could cause results to differ appears in the press release issued by Sophia Genetics today and in the documents and reports filed by Sophia Genetics from time to time with the Securities and Exchange Commission. During this call, we will present both IFRS and non-IFRS financial measures. A reconciliation of IFRS to non-IFRS measures is included in today's earnings press release, which is available on our website. With that, I will now turn the call over to Jurgi. Thanks, Kellen, and good morning, everyone. I will start with a brief recap of Q3 performance and an update on major growth drivers. I will then turn the call over to Ross, who will provide a more detailed update on the business. George will close with a review of our Q3 financial performanc...